Tuesday, July 16, 2019

STORM Therapeutics Pioneering New RNA Pathways to Novel Therapies

In August of 2018 the Food and Drug Administration (FDA) approved the first of a potentially game-changing class of drugs called small interfering ribonucleic acid (siRNA). FDA Commissioner Scott Gottlieb, MD...

The Fight Against Acute Microbial Resistance (AMR) goes Virtual – Acurx Developing Antimicrobials with...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) Bob DeLuccia is a man on the move with a single mission:  Addressing the worldwide epidemic of antimicrobial drug resistance, today commonly...

The Game-Changing Potential of Targeting RNA with Small Molecules: More Than Turning the Undruggable...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) Once considered impossible, targeting RNA with small molecules has the potential to be a game-changer. It’s convincing enough to industry veteran Michael...

WuXi AppTec Acquires Pharmapace to Enhance Biometrics Services for Clinical Development

Shanghai, China & San Diego, California May 6, 2019 - WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired...

WuXi AppTec Announces Strong First-Quarter 2019 Results

WuXi AppTec Announces Strong First-Quarter 2019 Results Revenue RMB2,769 Million, up 29.3% Net Profit Attributable to Owners of the Company RMB386 Million, up 33.0% Year-Over-Year Diluted EPS RMB0.33, up 6.5% Year-Over-Year (SHANGHAI, April 30,...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS